BioMarin Pharmaceutical (BMRN) Stock Analysis

November 11, 2026

This is a peer-relative look at BioMarin Pharmaceutical (BMRN): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for BioMarin Pharmaceutical (BMRN)
Profile Item	BMRN
Name	BioMarin Pharmaceutical Inc.
Country/Region	United States
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology
GICS Sub-Industry	Biotechnology
Market Capitalization	10.85 billion USD
Currency	USD
Exchange	Nasdaq
Listing Date	July 26, 1999
Security Type	Common Stock

Price Performance

Cumulative Growth

BMRN

GSPC

BioMarin Pharmaceutical (BMRN) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for BioMarin Pharmaceutical (BMRN) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for BioMarin Pharmaceutical (BMRN) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

BioMarin Pharmaceutical (BMRN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BMRN	Industry group median
Total Return (1Y)	8.82%	24.62%
Total Return (3Y, Annualized)	-12.54%	20.37%
Total Return (5Y, Annualized)	-7.51%	-4.02%

Risk Profile

Drawdown History

BMRN

GSPC

BioMarin Pharmaceutical (BMRN) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for BioMarin Pharmaceutical (BMRN) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

BioMarin Pharmaceutical (BMRN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BMRN	Industry group median
Volatility (1Y, Annualized)	35.50%	66.36%
Beta (5Y)	0.24	0.93
Max Drawdown (5Y)	-57.64%	-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. BMRN is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

BioMarin Pharmaceutical (BMRN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BMRN	Industry group median
Sharpe Ratio (1Y)	0.13	0.36
Sortino Ratio (1Y)	0.23	0.58

Profitability

ROE (TTM)

BioMarin Pharmaceutical (BMRN) has negative ROE of -0.31%. That can come from trailing losses or negative book equity, so it is a warning state rather than a clean capital-efficiency measure.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.31%

Group distribution

Max: 109.18%
Q3: 6.23%
BMRN: -0.31%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Largest peers

LLY: 86.02%
NVS: 24.33%
AZN: 22.57%
JNJ: 20.02%
MRK: 5.06%
BMRN: -0.31%
ABBV: --

Where BioMarin Pharmaceutical (BMRN) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

BioMarin Pharmaceutical (BMRN) has negative net margin of -0.52%. The trailing period ended in a net loss, so the bottom-line conversion read is a warning rather than a profitability strength.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.52%

Group distribution

Max: 18.05%
Q3: 4.78%
Median: 0.00%
BMRN: -0.52%
Q1: -4.14%
Min: -17.05%

Largest peers

LLY: 31.90%
AZN: 17.68%
NVS: 17.49%
JNJ: 16.20%
ABBV: 15.67%
MRK: 3.64%
BMRN: -0.52%

Where BioMarin Pharmaceutical (BMRN) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

BioMarin Pharmaceutical (BMRN) turns 26.58% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.58%

Group distribution

Max: 83.12%
BMRN: 26.58%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Largest peers

LLY: 53.66%
ABBV: 39.59%
MRK: 35.22%
NVS: 34.27%
AZN: 29.57%
BMRN: 26.58%
JNJ: 25.74%

Where BioMarin Pharmaceutical (BMRN) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

BioMarin Pharmaceutical (BMRN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BMRN	Industry group median
ROE (TTM)	-0.31%	-26.66%
ROA (TTM)	3.89%	-12.50%
Net Margin (TTM)	-0.52%	0.00%
Operating Margin (TTM)	26.58%	0.00%
Gross Margin (TTM)	53.21%	37.87%

Growth

Revenue Growth

BioMarin Pharmaceutical (BMRN) grew revenue 12.87%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

BioMarin Pharmaceutical (BMRN): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

BioMarin Pharmaceutical (BMRN) grew earnings per share -18.55%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.

BioMarin Pharmaceutical (BMRN): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

BioMarin Pharmaceutical (BMRN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BMRN	Industry group median
Revenue Growth (YoY)	12.87%	11.45%
Revenue Growth (3Y CAGR)	15.40%	9.94%
EPS Growth (YoY)	-18.55%	4.28%
EPS Growth (3Y CAGR)	33.89%	4.17%

Financial Strength

Current Ratio (MRQ)

BioMarin Pharmaceutical (BMRN) has current ratio of 2.44, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.44

Group distribution

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BMRN: 2.44
Min: 0.10

Largest peers

BMRN: 2.44
LLY: 1.39
MRK: 1.35
JNJ: 1.02
AZN: 1.01
NVS: 0.88
ABBV: 0.87

Where BioMarin Pharmaceutical (BMRN) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

BioMarin Pharmaceutical (BMRN) has debt-to-equity ratio of 0.67, in the higher-leverage quartile for its industry. The heavier reliance on borrowing can make earnings, rates, or refinancing conditions matter more.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67

Group distribution

Max: 1.42
BMRN: 0.67
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Largest peers

NVS: 1.29
LLY: 1.23
MRK: 1.20
BMRN: 0.67
AZN: 0.66
JNJ: 0.55
ABBV: --

Where BioMarin Pharmaceutical (BMRN) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

BioMarin Pharmaceutical (BMRN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BMRN	Industry group median
Current Ratio (MRQ)	2.44	5.52
Debt / Equity (MRQ)	0.67	0.15
Net Debt / EBITDA	4.04	1.08

Dividends

Dividend Yield (TTM)

BioMarin Pharmaceutical (BMRN) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

BMRN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.88%
ABBV: 2.40%
MRK: 2.29%
JNJ: 1.94%
AZN: 1.73%
LLY: 0.49%
BMRN: 0.00%

Where BioMarin Pharmaceutical (BMRN) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

BioMarin Pharmaceutical (BMRN) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

BMRN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 343.43%
ABBV: 117.35%
NVS: 90.46%
JNJ: 80.12%
AZN: 45.38%
LLY: 21.71%
BMRN: 0.00%

Where BioMarin Pharmaceutical (BMRN) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

BioMarin Pharmaceutical (BMRN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BMRN	Industry group median
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

No usable P/E ratio is available for BioMarin Pharmaceutical (BMRN) this period, so the trailing-earnings valuation read is skipped.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

Group distribution

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
BMRN: --

Largest peers

MRK: 148.21
ABBV: 50.05
LLY: 43.95
JNJ: 41.92
NVS: 31.02
AZN: 26.37
BMRN: --

BioMarin Pharmaceutical (BMRN) doesn’t report P/E ratio this period; the box shows the Pharmaceuticals, Biotechnology & Life Sciences group’s distribution and the dots its largest members.

P/S Ratio (TTM)

BioMarin Pharmaceutical (BMRN) trades at 2.97 on P/S ratio, in the lower sales-valuation quartile for its industry. That points to a cheaper revenue stream than most peers, with margin quality still doing the heavy lifting.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.97

Group distribution

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
BMRN: 2.97
Min: 0.01

Largest peers

LLY: 13.95
ABBV: 7.80
JNJ: 6.69
MRK: 5.37
NVS: 5.35
AZN: 4.63
BMRN: 2.97

Where BioMarin Pharmaceutical (BMRN) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

BioMarin Pharmaceutical (BMRN) trades at 1.73 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73

Group distribution

Max: 13.53
Q3: 6.54
Median: 3.25
BMRN: 1.73
Q1: 1.69
Min: -5.59

Largest peers

LLY: 29.96
NVS: 8.25
JNJ: 8.16
MRK: 8.06
AZN: 5.59
BMRN: 1.73
ABBV: -112.34

Where BioMarin Pharmaceutical (BMRN) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

BioMarin Pharmaceutical (BMRN) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: BMRN	Industry group median
P/E Ratio (TTM)	--	26.69
P/S Ratio (TTM)	2.97	7.30
P/B Ratio (MRQ)	1.73	3.25
Free Cash Flow Yield (TTM)	-0.15%	-1.66%